3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Capecitabine
27
pembrolizumab
19
Oxaliplatin
19
Fluorouracil
17
Cisplatin
17
Trastuzumab
14
Docetaxel
14
Leucovorin
11
Paclitaxel
8
Irinotecan
8
S 1 (combination)
7
Epirubicin
6
Cyclophosphamide
5
tegafur-gimeracil-oteracil
4
aldesleukin
4
Hyperthermic Intraperitoneal Chemotherapy
4
titanium silicide
3
spartalizumab
3
fludarabine phosphate
3
fludarabine
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Ramucirumab
3
Nivolumab
3
Indocyanine Green
3
Gemcitabine
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
Ado-Trastuzumab Emtansine
3
vistusertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Stomach Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled